Treatment outcomes of extranodal diffuse large B-cell lymphoma

Shu-nan QI,Ye-xiong LI,Qing-feng LIU,Hui FANG,Hua WANG,Jing JIN,Wei-hu WANG,Yong-wen SONG,Shu-lian WANG,Yue-ping LIU,Xin-fan LIU,Zi-hao YU
DOI: https://doi.org/10.3760/cma.j.issn.1004-4221.2009.02.101
2009-01-01
Abstract:Objective To analyze the clinical features and treatment outcomes of extranodal diffuse large B-cell lymphoma(DLBCL). Methods Ninety-nine consecutively diagnosed patients with extranodal DLBCL were reviewed. All patients were confirmed by a combination of morphologic and immunohistochemi-cal evaluation. The primary sites of extranodal DLBCL were the gastrointestine(n = 32) ,central nerve system (CNS)/testis(n=14) ,and other sites (n = 53). Results Extranodal DLBCL was characterized by a pre-dominance in old males,less frequency of B symptorns,a large proportion of stage Ⅰ-Ⅱ disease and low in-ternational prognostic factor(IP1) score. The 5-year overall survival(OS) rate for all patients was 78.9%. The corresponding OS rate was 82.5% for gastrointestinal origin, 37.0% for CNS and testis origin and 74.6% for other organ origin, respectively. On univariate analysis, performance status, IPI score and more than one extranedal site involvement were the prognostic predictors for 5-year OS. Conclusions Being a heterogeneous group of lymphomas, extranedal DLBCL has good prognosis except those derived from the CNS and testis.
What problem does this paper attempt to address?